Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 2 · 40%High 1 · 20%

Disease-free survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy

Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.93 [0.87, 1]
7 studies · 8903 participants
Moderate

Overall survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy

Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.92 [0.84, 1]
7 studies · 8902 participants
High

Grade ≥ 3 diarrhoea · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy

It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.12 [0.99, 1.25]
9 studies · 9551 participants
Very low

Hand‐foot syndrome (grade ≥ 3) · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy

Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 4.59 [2.97, 7.1]
5 studies · 5731 participants
Low

Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy

Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 0.14 [0.11, 0.16]
7 studies · 8087 participants
Moderate